AstraZeneca: Q4 & FY 2015 Results (AstraZeneca) - Feb 6, 2016 - Anticipated top-line data from P1/2 trial (NCT02027961) in combo with dabrafenib/trametinib in metastatic or unresectable melanoma in 2017; Anticipated completion of enrollment of P1 trial (NCT02118337) in combination with MEDI0680 for advanced malignancies in 2017; Anticipated top-line data from P1 trial (NCT02118337) in combination with MEDI0680 in advanced malignancies in 2018
Anticipated enrollment status • Anticipated P1 data • Anticipated P1/2 data • Melanoma • Oncology
|